Aptamers have several advantages over mAbs as a targeting moiety including: (i) smaller size that enables better tissue/tumor penetration; (ii) chemical synthesis which allows rapid and affordable scale-up; (iii) superior safety profile from lack of immunogenicity and short half-life which reduces ...
Henlius’ phase 3 clinical study of its innovative anti-PD-1 monoclonal antibody(mAb) HANSIZHUANG (serplulimab) as first-line treatment for patients with extensive-stage small cell lung cancer (ES-SCLC) was published as poster presentation...
We're excited to announce that ICE Bioscience will be participating in the AACR Annual Meeting 2024 from April 5-10 at the San Diego Convention Center. You can find us at booth#4228, where we'll be ready to dive into discussions about ourstate-of-the-artoncology services. Our dedicated i...
2024年4月5日-10日,第115届AACR年会在美国圣地亚哥举行,来自全球各地的超过22,500位肿瘤科学家、医生及相关企业代表注册参会。 会议现场图片(来源:X平台) AACR Annual Meeting 2024在X社交平台上共有6,290位参与者,推送了26,313个帖子,产生超过5.53亿次阅读。The Innovation本年度主要由医学及肿瘤相关X平台账号参与...
Bold Therapeutics announced that it will present two posters – a clinical poster (#CT149) and a translational research poster (#2259) – at the American Association for Cancer Research (AACR) Annual Meeting 2023 on April 14 - 19, 2023.
“the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American Association for Cancer Research (“AACR”) Annual Meeting 2024 in San Diego, California, from April 5-10, 2024. The oral and poster pr...
Panel b shows uncropped western blots from Fig 2 (Red rectangle indicates the blots used in Fig 2 for recombinant ENO1 and ENO2 proteins blotted with their respective antibodies (ENO1 antibody, 1:1000, Abcam ab155102; ENO2 antibody, 1:1000, Dako... [Show full abstract] 展开 ...
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held in San Diego, USA, from April 5-10, 2024. ...
From April 13 to 21, 2023, Director Li Kang from Department of Surgical Oncology was invited to attend the Annual Meeting 2023 of American Association for Cancer Research (AACR). At the meeting, he delivered a poster entitled "The predictive role of γδ T cells in colorectal cancer and ...
--Eli Lilly and Company today announced that preclinical data for agents targeting Nectin-4, KRAS G12D, and BRM will be presented at the American Association for Cancer Research Annual Meeting, taking place April 5-10 in San Diego. PT Session Title: Anti